explosion time ,finally time for a re-rating.., page-9

Indi, you are totally right on the stage of development for the drug. Its either late stage phase I or early phase II. The real question is the indication and the potential patient pool. Something that treats a common ailment is going to need a lot of patients for its clinical trials. If its for something esoteric, then it may not need a lot of units to do its clinical trials. The important thing is the continuation of the deal and we now know the customer's name. Thats a major leap forward.